New review reveals how non-genomic estrogen signaling undermines treatment response and fuels tumor progression Hormone receptor–positive breast ...
A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...
Atebimetinib targets MEK, a key control point in the MAPK pathway (RAS-RAF-MEK-ERK), which is pathologically activated in a majority of cancers, including approximately 97% of pancreatic cancers.
Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.
A new discovery by researchers from Adelaide University, in collaboration with Denmark's Carlsberg Research Laboratory, will ...
News-Medical.Net on MSN
Atypical mutation offers clues to personalized pancreatic cancer treatment
A new study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results